var data={"title":"Rifampin (rifampicin): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rifampin (rifampicin): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6910?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rifampin-rifampicin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rifampin (rifampicin): Patient drug information&quot;</a> and <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Rifampin (rifampicin): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218187\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rifadin;</li>\n      <li>RifAMPin+SyrSpend SF PH4</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218188\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Rifadin;</li>\n      <li>Rofact</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218238\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antitubercular Agent;</li>\n      <li>\n        Rifamycin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218192\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal prophylaxis:</b> Oral, IV: 600 mg twice daily for 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis, active (drug-susceptible): </b>Oral, IV: <b>Note:</b> Always administer in combination with other antitubercular drugs (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer&rsquo;s labeling: 10 mg/kg/day once daily (maximum: 600 mg/day)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations: ATS/CDC/IDSA Drug-susceptible tuberculosis guideline recommendations (Nahid 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Once-daily therapy: 10 mg/kg/day once daily (usual dose: 600 mg). <b>Note: </b>The preferred frequency of administration is once daily during the intensive and continuation phases; however, 5-days-per-week administration by directly observed therapy (DOT) is an acceptable alternative.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Twice-weekly or three-times-weekly DOT: 10 mg/kg/dose (usual dose: 600 mg) administered 2 or 3 times weekly (Nahid 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Regimens: </i>Treatment regimens for pulmonary tuberculosis and tuberculous meningitis consist of an initial 2-month phase of a 4-drug regimen, followed by a continuation phase of an additional 4 to 7 months of rifampin and isoniazid for pulmonary tuberculosis and a continuation phase of an additional 7 to 10 months of rifampin and isoniazid for tuberculous meningitis (optimal duration is not defined although continuation phase must continue for a minimum of 7 additional months). Adjunctive corticosteroid therapy (eg, dexamethasone, prednisolone) tapered over 6 to 8 weeks is also recommended for tuberculous meningitis. Rifampin frequency and dosing differs depending on treatment regimen selected; consult current Drug-sensitive TB guidelines (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis, latent infection (LTBI):</b> As an alternative to isoniazid: Oral, IV: 10 mg/kg/day (maximum: 600 mg/day) for 4 months. <b>Note:</b> Combination with pyrazinamide should not generally be offered (<i>MMWR</i>, Aug 8, 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anaplasmosis, mild cases (patients with severe allergy to doxycycline) (off-label use):</b> Oral: 300 mg twice daily for 7 to 10 days. <b>Note:</b> Rifampin is not an effective agent for Rocky Mountain spotted fever (RMSF); ensure that RMSF has been ruled out prior to use. Rifampin is also not effective for Lyme disease; if co-infection with <i>B. burgdorferi</i> is suspected, treat with an additional appropriate antimicrobial agent (CDC [Biggs 2016]; IDSA [Wormser 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brain abscess, empyema, and epidural abscess (MRSA) (off-label use): </b>Oral, IV: 600 mg once daily or 300 to 450 mg twice daily with concomitant vancomycin for 4 to 6 weeks (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brucellosis (off-label use):</b> Oral: 600 to 900 mg once daily for 6 weeks; use in combination with doxycycline (WHO 2006). Additional data may be necessary to further define the role of rifampin in this condition.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cholestatic pruritus (off-label use) (Lindor 2009):</b> Oral: Dose based on bilirubin value:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bilirubin &lt; 3 mg/dL: 150 mg daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Bilirubin &ge;3 mg/dL: 150 mg twice daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Device-related osteoarticular infection (MRSA) (off-label use):</b> Oral: 600 mg once daily or 300 to 450 mg twice daily in combination with another antistaphylococcal antibiotic (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (prosthetic valve) (off-label use):</b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>MRSA:</i> 300 mg every 8 hours for at least 6 weeks (combine with vancomycin for the entire duration of therapy and gentamicin for the first 2 weeks) (IDSA [Liu 2011]; AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>MSSA:</i> 300 mg every 8 hours for at least 6 weeks (combine with nafcillin or oxacillin for the entire duration of therapy and gentamicin for the first 2 weeks) (AHA [Baddour 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Group A streptococci (GAS) chronic carrier, treatment (off-label use): </b>Oral: 20 mg/kg/day once daily (maximum: 600 mg daily) for the last 4 days of treatment when combined with oral penicillin V <b>or</b> 20 mg/kg/day in 2 divided doses (maximum: 600 mg daily) for 4 days when combined with intramuscular benzathine penicillin G (IDSA [Shulman 2012])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>H. influenzae</i> type B, chemoprophylaxis (off-label use):</b> Oral: 600 mg once daily for 4 days (<i>Red Book</i> [AAP] 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leprosy (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lepromatous (multibacillary):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Hansen Disease Program: 600 mg once daily for 24 months in combination with clofazimine and dapsone (NHDP [HRSA 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">World Health Organization: 600 mg once monthly for 12 months in combination with clofazimine and dapsone (WHO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tuberculoid (paucibacillary):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Hansen Disease Program: 600 mg once daily for 12 months in combination with dapsone (NHDP [HRSA 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">World Health Organization: 600 mg once monthly for 6 months in combination with dapsone (WHO 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningitis due to </b> <b><i>S. pneumoniae</i></b> <b>or staphylococci (off-label use):</b> Oral, IV: 600 mg once daily; use in combination with other antimicrobials (IDSA [Tunkel 2004])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nasal decolonization of </b> <b><i>Staphylococcus aureus </i></b> <b>(off-label use):</b> Oral, IV: 600 mg/day for 5 to 10 days; <b>Note: Must use in combination with at least one other systemic antistaphylococcal antibiotic.</b> Not recommended as first-line drug for decolonization; evidence is weak for use in patients with recurrent infections (IDSA [Liu 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nontuberculous mycobacterial disease, pulmonary (off-label use): </b> Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>M. avium</i> complex (nodular/bronchiectatic disease) (ATS/IDSA [Griffith 2007]): 600 mg 3 times weekly in combination with a 3-times-weekly regimen of a macrolide (azithromycin or clarithromycin) and ethambutol; continue treatment until patient is culture negative on therapy for 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>M. avium</i> complex (severe nodular/bronchiectatic or cavitary disease) (ATS/IDSA [Griffith 2007]): 600 mg (450 mg in patients weighing &lt;50 kg) once daily in combination with daily macrolide (azithromycin or clarithromycin) and ethambutol therapy; continue treatment until patient is culture negative on therapy for 1 year. May also consider addition of 3 times weekly amikacin or streptomycin early in therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>M. avium</i> complex (cystic fibrosis patients) (Floto 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&lt;50 kg: 450 mg once daily in combination with daily macrolide (azithromycin [preferred] or clarithromycin) and ethambutol therapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;50 kg: 600 mg once daily in combination with daily macrolide (azithromycin [preferred] or clarithromycin) and ethambutol therapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>M. kansasii</i> (ATS/IDSA [Griffith 2007]): 600 mg once daily in combination with daily ethambutol and isoniazid therapy; continue treatment until patient is culture negative on therapy for 1 year.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Osteomyelitis (MRSA) (off-label use):</b> Oral, IV: 600 mg once daily or 300 to 450 mg twice daily for at least 8 weeks with concomitant trimethoprim/sulfamethoxazole, linezolid or clindamycin (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prosthetic joint infection (off-label use): </b> <i>Staphylococci (oxacillin-susceptible or oxacillin-resistant):</i> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Debridement and prosthesis retention or following 1-stage exchange, acute treatment: 300 to 450 mg every 12 hours in combination with an IV antistaphylococcal antibiotic for 2 to 6 weeks (IDSA [Osmon 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Debridement and prosthesis retention or following 1-stage exchange, chronic treatment:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Total ankle, elbow, hip, or shoulder arthroplasty: 300 to 450 mg every 12 hours in combination with an oral antistaphylococcal antibiotic for 3 months (IDSA [Osmon 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Total knee arthroplasty: 300 to 450 mg every 12 hours in combination with an oral antistaphylococcal antibiotic for 6 months (IDSA [Osmon 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Septic thrombosis of cavernous or dural venous sinus (MRSA) (off-label use):</b> Oral, IV: 600 mg once daily or 300 to 450 mg twice daily with concomitant vancomycin for 4 to 6 weeks (IDSA [Liu 2011])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218215\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Rifampin (rifampicin): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis, active (drug-susceptible) (excludes meningitis):</b> Oral, IV: Use as part of a multidrug regimen:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s labeling: Infants, Children, and Adolescents: 10 to 20 mg/kg/<b>day</b> once daily (maximum: 600 mg/<b>day</b>)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate dosing: ATS/CDC/IDSA Drug-susceptible tuberculosis guideline recommendations (Nahid 2016):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Dosing: </i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Once-daily therapy: <b>Note:</b> The preferred frequency of administration is once daily during the intensive and continuation phases; however, 5-days-per-week administration by directly observed therapy (DOT) is an acceptable alternative.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants, Children, and Adolescents &lt;15 years and &le;40 kg: 10 to 20 mg/kg/dose once daily; maximum dose: 600 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children and Adolescents &lt;15 years and &gt;40 kg and Adolescents &ge;15 years: 10 mg/kg/dose once daily (usual dose: 600 mg)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Three-times-weekly directly observed therapy (DOT): <b>Note:</b> Although suggested dosing based on experience with twice-weekly regimen; experts suggest three-times-weekly regimens are more effective than twice-weekly DOT regimens; three-times-weekly DOT may be used as part of an intensive phase and/or continuation phase dosing regimen; consult guidelines for specific information.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Infants, Children, and Adolescents &lt;15 years and &le;40 kg: 10 to 20 mg/kg/dose administered three times weekly; maximum dose: 600 mg/dose.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Children and Adolescents &lt;15 years and &gt;40 kg and Adolescents &ge;15 years: 10 mg/kg/dose (usual dose: 600 mg) administered 3 times weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Regimens:</i> Treatment regimens for pulmonary tuberculosis consist of an initial 2-month phase of a 4-drug regimen, followed by a continuation phase of an additional 4 to 7 months of rifampin and isoniazid. Rifampin frequency and dosing differs depending on treatment regimen selected; consult current Drug-sensitive TB guidelines (Nahid 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis, latent infection (LTBI):</b> As an alternative to isoniazid: Children: 10 to 20 mg/kg/<b>day</b> (maximum: 600 mg/day) for 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Group A streptococci (GAS) chronic carrier, treatment (off-label use):</b> Children and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Anaplasmosis, mild cases (patients with severe allergy to doxycycline) (off-label use):</b> Children and Adolescents: Oral: 20 mg/kg/<b>day</b> in 2 divided doses, not to exceed 300 mg/dose. <b>Note:</b> Rifampin is not an effective agent for Rocky Mountain spotted fever (RMSF); ensure that RMSF has been ruled out prior to use. Rifampin is also not effective for Lyme disease; if co-infection with <i>B. burgdorferi</i> is suspected, treat with an additional appropriate antimicrobial agent (CDC [Biggs 2016]; IDSA [Wormser 2006]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endocarditis, treatment (prosthetic valve/material) (off-label use): Note: </b>Use in combination with other antibiotics:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Empiric therapy:</i> Children and Adolescents: Oral, IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Early infection (&le;1 year postop)/nosocomial infection associated with cannulation: 20 mg/kg/<b>day</b> divided every 8 hours; maximum daily dose: 900 mg/<b>day</b> (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Late infection (&gt;1 year postop): 15 to 20 mg/kg/<b>day</b> divided every 12 hours; maximum daily dose: 600 mg/<b>day</b> (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>MRS</i>\n      <i>A infection:</i> Infants, Children, and Adolescents: Oral, IV: 15 mg/kg/<b>day</b> divided every 8 hours; maximum daily dose: 900 mg/<b>day</b> (IDSA [Liu 2011])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>H. influenzae </i></b> <b>prophylaxis (off-label use):</b> Oral, IV: Infants and Children: 20 mg/kg/<b>day</b> every 24 hours for 4 days, not to exceed 600 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Leprosy (off-label use):</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Lepromatous (multibacillary):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Hansen Disease Program: Children and Adolescents: 10 to 20 mg/kg/dose once daily (maximum dose: 600 mg/dose) for 24 months in combination with clofazimine and dapsone (NHDP [HRSA 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">World Health Organization (WHO 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Children &lt;10 years:</i> 10 mg/kg/dose once monthly for 12 months in combination with clofazimine and dapsone</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Children &ge;10 years and Adolescents:</i> 450 mg once monthly for 12 months in combination with clofazimine and dapsone</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tuberculoid (paucibacillary):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">National Hansen Disease Program: Children and Adolescents: 10 to 20 mg/kg/dose once daily (maximum dose: 600 mg/dose) for 12 months in combination with dapsone (NHDP [HRSA 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">World Health Organization (WHO 2012):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Children &lt;10 years: </i>10 mg/kg/dose once monthly for 6 months in combination with dapsone</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Children &ge;10 years and Adolescents: </i>450 mg once monthly for 6 months in combination with dapsone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal prophylaxis:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1 month: 10 mg/kg/<b>day</b> in divided doses every 12 hours for 2 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: 20 mg/kg/<b>day</b> in divided doses every 12 hours for 2 days (maximum: 600 mg/dose)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nasal carriers of </b> <b><i>Staphylococcus aureus </i></b> <b>(off-label use):</b> Oral, IV: 15 mg/kg/<b>day</b> divided every 12 hours for 5 to 10 days; <b>Note: Must use in combination with at least one other systemic antistaphylococcal antibiotic.</b> Not recommended as first-line drug for decolonization; evidence is weak for use in patients with recurrent infections (IDSA [Liu 2011]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218193\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218194\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Treatment of drug-susceptible TB: Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;30 mL/minute: 600 mg once daily or 600 mg administered 3 times weekly (Nahid 2016)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis: 600 mg once daily or 600 mg administered 3 times weekly; administer after hemodialysis on the day of dialysis (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218195\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling; use with caution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218158\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rifadin: 150 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rifadin: 300 mg [DSC] [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 150 mg, 300 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rifadin: 600 mg (1 ea) [contains sodium formaldehyde sulfoxylate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 600 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RifAMPin+SyrSpend SF PH4: 25 mg/mL (120 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218142\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50027244\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">RifAMPin+SyrSpend SF PH4 is a compounding kit. Refer to manufacturer's labeling for compounding instructions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218162\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">IV: Administer IV preparation by slow IV infusion over 30 minutes to 3 hours at a final concentration not to exceed 6 mg/mL. Do <b>not</b> administer IM or SubQ. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Oral: Administer on an empty stomach (ie, 1 hour prior to, or 2 hours after meals or antacids) to increase total absorption. The compounded oral suspension must be shaken well before using. May mix contents of capsule with applesauce or jelly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218161\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Meningococcal prophylaxis:</b> Treatment of asymptomatic carriers of <i>Neisseria meningitidis</i> to eliminate meningococci from the nasopharynx</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Tuberculosis:</b> Treatment of tuberculosis in combination with other agents</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25715118\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Anaplasmosis; Brain abscess, empyema, and epidural abscess (MRSA); Brucellosis; Cholestatic pruritus (adults); Device-related osteoarticular infection (MRSA) (adults); Endocarditis (prosthetic valve), treatment (adults); Endocarditis (prosthetic valve), treatment (pediatric); Group A streptococci (GAS) chronic carrier (treatment); Haemophilus influenzae type B, chemoprophylaxis; Leprosy; Meningitis due to Streptococcus pneumoniae or staphylococci; Nasal decolonization of S. aureus; Nontuberculous mycobacterial disease, pulmonary; Osteomyelitis (MRSA); Prosthetic joint infection; Septic thrombosis of cavernous or dural venous sinus (MRSA)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218247\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rifadin may be confused with Rifater, Ritalin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">RifAMPin may be confused with ribavirin, rifabutin, Rifamate, rifapentine, rifAXIMin </p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218149\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Decreased blood pressure, flushing, shock, vasculitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Ataxia, behavioral changes, confusion, dizziness, drowsiness, fatigue, headache, lack of concentration, myasthenia, numbness, peripheral pain, sore mouth</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Erythema multiforme, pemphigoid reaction, pruritus, skin rash, Stevens-Johnson syndrome, toxic epidermal necrolysis, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Adrenocortical insufficiency, menstrual disease</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal cramps, anorexia, dental discoloration, diarrhea, epigastric distress, flatulence, glossalgia, heartburn, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Hemoglobinuria, hematuria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Decreased hemoglobin, disseminated intravascular coagulation, eosinophilia, hemolysis, hemolytic anemia, leukopenia, thrombocytopenia (especially with high-dose therapy)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests, hepatic insufficiency, hyperbilirubinemia, jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immunologic: DRESS Syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Myopathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis, visual disturbance</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Acute renal failure, interstitial nephritis, renal insufficiency, renal tubular necrosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea, flu-like symptoms, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Agranulocytosis, anaphylaxis, cerebral hemorrhage, facial edema, hepatitis (including shock-like syndrome with hepatic involvement), increased blood urea nitrogen, increased uric acid, peripheral edema, pseudomembranous colitis, psychosis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218166\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to rifampin, any rifamycins, or any component of the formulation; concurrent use of atazanavir, darunavir, fosamprenavir, ritonavir/saquinavir, saquinavir, or tipranavir</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Jaundice associated with reduced bilirubin excretion; premature and newborn infants; breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218146\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Flu-like syndrome: Regimens of &gt;600 mg once or twice weekly in adults have been associated with a high incidence of adverse reactions including a flu-like syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: May cause thrombocytopenia, leukopenia, or anemia with regimens &gt;600 mg once or twice weekly in adults.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatotoxicity: May cause hepatic dysfunction; fatal cases have occurred in patients with hepatic disease taking rifampin with other hepatotoxic agents. Closely monitor hepatic function and discontinue use if hepatocellular damage occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperbilirubinemia: Hyperbilirubinemia may occur early in therapy as a result of competition between rifampin and bilirubin for excretory pathways in the liver. Discontinue therapy if hyperbilirubinemia occurs in conjunction with clinical symptoms or any signs of significant hepatocellular damage develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, including severe and potentially fatal reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, have occurred with anti-tuberculosis therapy. Signs and symptoms of hypersensitivity reactions may include fever, rash, urticaria, angioedema, hypotension, acute bronchospasm, conjunctivitis, thrombocytopenia, neutropenia, elevated liver transaminases, or flu-like syndrome. Monitor patients for signs/symptoms of hypersensitivity; discontinue therapy if signs/symptoms suggestive of hypersensitivity (eg, fever, lymphadenopathy, eosinophilia, liver abnormalities) occur, even if rash is not evident.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Alcoholism: Use with caution in patients with a history of alcoholism (even if ethanol consumption is discontinued during therapy).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Diabetes mellitus: Use with caution in patients with diabetes mellitus; management of diabetes may be more difficult in patients taking rifampin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution and close monitoring in patients with hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Meningococcal disease: Do not use for treatment of meningococcal disease, only for short-term treatment of asymptomatic carrier states.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Porphyria: Use with caution in patients with porphyria; exacerbations have been reported due to enzyme-inducing properties.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate administration: Do not administer IV form via IM or SubQ routes; restart infusion at another site if extravasation occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Compliance: Monitor for compliance in patients on intermittent therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact lenses: Remove soft contact lenses during therapy since permanent staining may occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Discoloration: Teeth (may be permanent), urine, feces, saliva, sweat, and tears may be discolored (yellow, orange, red, or brown).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218233\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of OATP1B1/SLCO1B1, P-glycoprotein/ABCB1; <b>Inhibits</b> OATP1B1/SLCO1B1; <b>Induces</b> CYP1A2 (weak), CYP2A6 (strong), CYP2B6 (moderate), CYP2C19 (strong), CYP2C8 (moderate), CYP2C9 (moderate), CYP3A4 (strong), P-glycoprotein/ABCB1, UGT1A1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218151\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9864&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abemaciclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abemaciclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Abiraterone Acetate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Abiraterone Acetate.  Management: Avoid whenever possible.  If such a combination cannot be avoided, increase abiraterone acetate dosing frequency from once daily to twice daily during concomitant use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acalabrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Acalabrutinib.  Management: Avoid co-administration of strong CYP3A inducers in patients taking acalabrutinib. If strong CYP3A inducers cannot be avoided, increase the dose of acalabrutinib to 200 mg twice daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Afatinib: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Afatinib.  Management: Per US labeling: if requiring chronic use of P-gp inducers, increase afatinib dose by 10mg as tolerated; reduce to original afatinib dose 2-3 days after stopping P-gp inducers.  Per Canadian labeling: avoid combination if possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alfentanil: Rifamycin Derivatives may decrease the serum concentration of Alfentanil.  Management: Monitor closely for decreased alfentanil effectiveness.  Increased alfentanil doses will likely be needed.  Alternatively, changing from alfentanil to a different opioid anesthetic (e.g., sufentanil) may also be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May enhance the QTc-prolonging effect of RifAMPin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amiodarone: RifAMPin may decrease serum concentrations of the active metabolite(s) of Amiodarone. Specifically, desethylamiodarone concentrations may decrease. RifAMPin may decrease the serum concentration of Amiodarone.  Management: Seek alternatives.  When used together, monitor closely for decreased amiodarone concentrations/effects.  Dose adjustment may be needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected. Rifamycin Derivatives may decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Management: Avoid these combinations when possible.  Voriconazole and isavuconazonium are considered contraindicated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihepaciviral Combination Products: CYP3A4 Inducers (Strong) may decrease the serum concentration of Antihepaciviral Combination Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apalutamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apixaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apixaban. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Apremilast: CYP3A4 Inducers (Strong) may decrease the serum concentration of Apremilast. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aprepitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Aprepitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of ARIPiprazole.  Management: Double the oral aripiprazole dose and closely monitor. Reduce oral aripiprazole dose to 10-15 mg/day (for adults) if the inducer is discontinued. Avoid use of strong CYP3A4 inducers for more than 14 days with extended-release injectable aripiprazole.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ARIPiprazole Lauroxil: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil.  Management: Patients taking the 441 mg dose of aripiprazole lauroxil increase their dose to 662 mg if used with a strong CYP3A4 inducer for more than 14 days. No dose adjustment is necessary for patients using the higher doses of aripiprazole lauroxil.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Artemether: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Artemether. Specifically, dihydroartemisinin concentrations may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Artemether. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Asunaprevir: RifAMPin may decrease the serum concentration of Asunaprevir. This effect is most likely with longer-term coadministration; single-dose rifampin may increase asunaprevir concentrations. RifAMPin may increase the serum concentration of Asunaprevir. This effect is likely following only single-dose or short-term rifampin administration.  Longer-term coadministration is likely to result in decreased asunaprevir concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ataluren: RifAMPin may decrease the serum concentration of Ataluren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atazanavir: RifAMPin may decrease the serum concentration of Atazanavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Atovaquone: Rifamycin Derivatives may decrease the serum concentration of Atovaquone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Axitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: Rifamycin Derivatives may increase the metabolism of Barbiturates. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bazedoxifene: RifAMPin may decrease the serum concentration of Bazedoxifene. This may lead to loss of efficacy or, if bazedoxifene is combined with estrogen therapy, an increased risk of endometrial hyperplasia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bedaquiline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bedaquiline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benperidol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzhydrocodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Benzhydrocodone. Specifically, the serum concentrations of hydrocodone may be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Rifamycin Derivatives may decrease the serum concentration of Beta-Blockers. <b> Exceptions: </b>Atenolol; Carteolol (Ophthalmic); Levobunolol; Metipranolol; Nadolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bictegravir: RifAMPin may decrease the serum concentration of Bictegravir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Boceprevir: RifAMPin may decrease the serum concentration of Boceprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bortezomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bortezomib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: RifAMPin may decrease the serum concentration of Bosentan. Following the initial several weeks of concurrent rifampin, this effect is most likely. RifAMPin may increase the serum concentration of Bosentan. This effect is most likely to be observed within the initial few weeks of concurrent therapy (and may be greatest immediately following initiation of the combination).  Management: Weekly monitoring of liver function tests during the first 4 weeks of concurrent therapy is recommended, with a return to normal recommended monitoring thereafter as appropriate.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Bosutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brentuximab Vedotin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brexpiprazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brexpiprazole.  Management: If brexpiprazole is used together with a strong CYP3A4 inducer, the brexpiprazole dose should gradually be doubled over the course of 1 to 2 weeks.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brigatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Brigatinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brivaracetam: RifAMPin may decrease the serum concentration of Brivaracetam.  Management: Increase the brivaracetam dose by up to 100% (ie, double the dose) if used together with rifampin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Buprenorphine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Buprenorphine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BusPIRone: CYP3A4 Inducers (Strong) may decrease the serum concentration of BusPIRone.  Management: Consider alternatives to this combination. If coadministration of these agents is deemed necessary, monitor patients for reduced buspirone effects and increase buspirone doses as needed.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cabozantinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cabozantinib.  Management: Avoid use of strong CYP3A4 inducers with cabozantinib if possible. If combined, cabozantinib dose adjustments are recommended and vary based on the cabozantinib product used and the indication for use. See monograph for details.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcifediol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Calcifediol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Calcium Channel Blockers: Rifamycin Derivatives may decrease the serum concentration of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers.  Management: The labeling for some US and Canadian calcium channel blockers contraindicate use with rifampin, however recommendations vary. Consult appropriate labeling.<b> Exceptions: </b>Clevidipine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Canagliflozin: RifAMPin may decrease the serum concentration of Canagliflozin.  Management: Consider increasing canagliflozin dose to 300 mg/day in patients with estimated GFR &gt;60 mL/min/1.73 m2 who tolerate canagliflozin 100 mg/day and require greater glycemic control. Consider alternatives in patients with estimated GFR 45-60 mL/min/1.73 m2.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabidiol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabidiol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabis: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cannabis. More specifically, tetrahydrocannabinol and cannabidiol serum concentrations may be decreased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cariprazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cariprazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Caspofungin: RifAMPin may decrease the serum concentration of Caspofungin.  Management: Caspofungin prescribing information recommends using a dose of 70 mg daily in adults (or 70 mg/m<sup>2</sup>, up to a maximum of 70 mg, daily in pediatric patients) who are also receiving rifampin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Celiprolol: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Celiprolol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ceritinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Systemic): RifAMPin may increase the metabolism of Chloramphenicol (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Citalopram: RifAMPin may decrease the serum concentration of Citalopram. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clarithromycin: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clarithromycin. Clarithromycin may increase the serum concentration of CYP3A4 Inducers (Strong). CYP3A4 Inducers (Strong) may decrease the serum concentration of Clarithromycin.  Management: Consider alternative antimicrobial therapy for patients receiving a CYP3A inducer. Drugs that enhance the metabolism of clarithromycin into 14-hydroxyclarithromycin may alter the clinical activity of clarithromycin and may impair clarithromycin efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Clopidogrel: CYP2C19 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Clopidogrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: CYP3A4 Inducers (Strong) may decrease the serum concentration of CloZAPine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobicistat: RifAMPin may decrease the serum concentration of Cobicistat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cobimetinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Cobimetinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Copanlisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Copanlisib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Corticosteroids (Systemic). <b> Exceptions: </b>Hydrocortisone (Systemic); PrednisoLONE (Systemic); PredniSONE.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Crizotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Crizotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Rifamycin Derivatives may increase the metabolism of CycloSPORINE (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2A6 Substrates (High risk with Inducers): CYP2A6 Inducers (Strong) may increase the metabolism of CYP2A6 Substrates (High risk with Inducers).  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2B6 Substrates (High risk with Inducers): CYP2B6 Inducers (Moderate) may decrease the serum concentration of CYP2B6 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C19 Substrates (High risk with Inducers): CYP2C19 Inducers (Strong) may increase the metabolism of CYP2C19 Substrates (High risk with Inducers).  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP2C9 Substrates (High risk with Inducers): CYP2C9 Inducers (Moderate) may decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Substrates (High risk with Inducers): CYP3A4 Inducers (Strong) may increase the metabolism of CYP3A4 Substrates (High risk with Inducers).  Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<b> Exceptions: </b>Benzhydrocodone; Buprenorphine; Etizolam; HYDROcodone; Zolpidem.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible. Closely monitor for decreased levels/effects of dabigatran if concomitantly administering P-glycoprotein inducers, particularly strong inducers.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dabrafenib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Daclatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Darunavir: RifAMPin may decrease the serum concentration of Darunavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasabuvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasabuvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dasatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dasatinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing dasatinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: RifAMPin may decrease the serum concentration of Deferasirox.  Management: Avoid combination when possible; if the combination must be used, consider a 50% increase in initial deferasirox dose, with monitoring of serum ferritin concentrations and clinical responses to guide further dosing.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deflazacort: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Deflazacort. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delamanid: CYP3A4 Inducers (Strong) may decrease the serum concentration of Delamanid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Delavirdine: Rifamycin Derivatives may increase the metabolism of Delavirdine. Delavirdine may increase the serum concentration of Rifamycin Derivatives. Specifically, Rifabutin serum concentration may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexamethasone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Dexamethasone (Systemic).  Management: Consider dexamethasone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diclofenac (Systemic): CYP2C9 Inducers (Moderate) may decrease the serum concentration of Diclofenac (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dienogest: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dienogest.  Management: Avoid use of dienogest for contraception when using medications that induce CYP3A4 and for at least 28 days after discontinuation of a CYP3A4 inducer.  An alternative form of contraception should be used during this time.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diethylstilbestrol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Diethylstilbestrol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DilTIAZem: RifAMPin may decrease the serum concentration of DilTIAZem. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Disopyramide: RifAMPin may decrease the serum concentration of Disopyramide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dolutegravir: RifAMPin may decrease the serum concentration of Dolutegravir.  Management: Increase dolutegravir dose to 50 mg twice daily in adults or children. Consider alternatives to rifampin for INSTI experienced patients with clinically suspected INSTI resistance or certain INSTI associated resistance substitutions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxercalciferol: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Doxercalciferol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): CYP3A4 Inducers (Strong) may decrease the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to strong CYP3A4 inducers in patients treated with doxorubicin. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DOXOrubicin (Conventional): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of DOXOrubicin (Conventional).  Management: Seek alternatives to P-glycoprotein inducers in patients treated with doxorubicin whenever possible. One U.S. manufacturer (Pfizer Inc.) recommends that these combinations be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxycycline: RifAMPin may decrease the serum concentration of Doxycycline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronedarone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Dronedarone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Edoxaban: RifAMPin may decrease the serum concentration of Edoxaban. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Efavirenz: RifAMPin may decrease the serum concentration of Efavirenz.  Management: Increase efavirenz adult dose to 800 mg daily in patients weighing over 50 kg.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elbasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Elbasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eliglustat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Eliglustat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: RifAMPin may increase the serum concentration of Eluxadoline.  Management: Decrease the eluxadoline dose to 75 mg twice daily if combined with rifampin and monitor patients for increased eluxadoline effects/toxicities.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Elvitegravir: RifAMPin may decrease the serum concentration of Elvitegravir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Enzalutamide.  Management: Consider using an alternative agent that has no or minimal CYP3A4 induction potential when possible.  If this combination cannot be avoided, increase the dose of enzalutamide from 160 mg daily to 240 mg daily.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Erlotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Erlotinib.  Management: Avoid combination if possible.  If combination must be used, increase erlotinib dose by 50 mg increments every 2 weeks as tolerated, to a maximum of 450 mg/day.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Esomeprazole: RifAMPin may decrease the serum concentration of Esomeprazole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Estriol (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estriol (Topical): CYP3A4 Inducers (Strong) may decrease the serum concentration of Estriol (Topical). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Rifamycin Derivatives may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Contraceptive failure is possible.  Management: Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide.  If these combinations cannot be avoided, monitor patients closely for diminished etoposide response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etoposide Phosphate: CYP3A4 Inducers (Strong) may decrease the serum concentration of Etoposide Phosphate.  Management: When possible, seek alternatives to strong CYP3A4-inducing medications in patients receiving etoposide phosphate.  If these combinations cannot be avoided, monitor patients closely for diminished etoposide phosphate response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Etravirine: Rifamycin Derivatives may decrease the serum concentration of Etravirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Everolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Everolimus.  Management: Avoid concurrent use of strong CYP3A4 inducers, but if strong CYP3A4 inducers cannot be avoided, consider gradually (in 5 mg increments) increasing the everolimus dose from 10 mg/day to 20 mg/day (adult doses).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Evogliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Evogliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Exemestane: CYP3A4 Inducers (Strong) may decrease the serum concentration of Exemestane.  Management: Exemestane U.S. product labeling recommends using an increased dose (50 mg/day) in patients receiving concurrent strong CYP3A4 inducers. The Canadian product labeling does not recommend a dose adjustment  with concurrent use of strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">FentaNYL: CYP3A4 Inducers (Strong) may decrease the serum concentration of FentaNYL. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fexofenadine: RifAMPin may decrease the serum concentration of Fexofenadine. RifAMPin may increase the serum concentration of Fexofenadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fimasartan: RifAMPin may increase the serum concentration of Fimasartan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flibanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Flibanserin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosamprenavir: RifAMPin may decrease the serum concentration of Fosamprenavir. Specifically, concentrations of amprenavir (active metabolite) may be decreased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosaprepitant: RifAMPin may decrease the serum concentration of Fosaprepitant. More specifically, rifampin may decrease concentrations of the active metabolite aprepitant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: RifAMPin may decrease the serum concentration of Fosphenytoin.  Management: Seek alternatives when possible. If used together, monitor closely for decreased serum phenytoin concentrations following rifampin initiation/dose increase, or increased concentrations and toxic effects following rifampin discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gefitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Gefitinib.  Management: In the absence of severe adverse reactions, increase gefitinib dose to 500 mg daily in patients receiving strong CYP3A4 inducers; resume 250 mg dose 7 days after discontinuation of the strong inducer.  Carefully monitor clinical response.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemfibrozil: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. See separate drug interaction monographs for agents listed as exceptions.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gemigliptin: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Gemigliptin. CYP3A4 Inducers (Strong) may decrease the serum concentration of Gemigliptin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gestrinone: RifAMPin may decrease the serum concentration of Gestrinone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glecaprevir and Pibrentasvir: RifAMPin may decrease the serum concentration of Glecaprevir and Pibrentasvir. RifAMPin may increase the serum concentration of Glecaprevir and Pibrentasvir. Specifically, a single dose of rifampin may increase glecaprevir/pibrentasvir concentrations, while chronic daily use of rifampin may decrease glecaprevir/pibrentasvir concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Grazoprevir: RifAMPin may decrease the serum concentration of Grazoprevir. Conversely, single doses of Rifampin may increase Grazoprevir concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">GuanFACINE: CYP3A4 Inducers (Strong) may decrease the serum concentration of GuanFACINE.  Management: Increase the guanfacine dose by up to double when initiating concomitant therapy with strong CYP3A4 inducers. Increase guanfacine dose gradually over 1-2 weeks if strong CYP3A4 inducer therapy is just beginning.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HMG-CoA Reductase Inhibitors (Statins): Rifamycin Derivatives may decrease the serum concentration of HMG-CoA Reductase Inhibitors (Statins).  Management: Consider use of noninteracting antilipemic agents (note: pitavastatin concentrations may increase with rifamycin treatment).  Monitor for altered HMG-CoA reductase inhibitor effects. Rifabutin and fluvastatin, or possibly pravastatin, may pose lower risk.<b> Exceptions: </b>Pitavastatin; Rosuvastatin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">HYDROcodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of HYDROcodone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydrocortisone (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of Hydrocortisone (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ibrutinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ibrutinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Idelalisib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Idelalisib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ifosfamide: CYP3A4 Inducers (Strong) may increase serum concentrations of the active metabolite(s) of Ifosfamide. CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: Rifamycin Derivatives may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with the rifamycin derivatives when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Imatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Imatinib.  Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indinavir: RifAMPin may decrease the serum concentration of Indinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Irinotecan Products: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Irinotecan Products. Specifically, serum concentrations of SN-38 may be reduced. CYP3A4 Inducers (Strong) may decrease the serum concentration of Irinotecan Products. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isavuconazonium Sulfate: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Isavuconazonium Sulfate. Specifically, CYP3A4 Inducers (Strong) may decrease isavuconazole serum concentrations. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Isoniazid: Rifamycin Derivatives may enhance the hepatotoxic effect of Isoniazid. Even so, this is a frequently employed combination regimen. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itraconazole: CYP3A4 Inducers (Strong) may decrease the serum concentration of Itraconazole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivabradine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivabradine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ivacaftor: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ivacaftor. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixabepilone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixabepilone.  Management: Avoid this combination whenever possible.  If this combination must be used, a gradual increase in ixabepilone dose from 40 mg/m<sup>2</sup> to 60 mg/m<sup>2</sup> (given as a 4-hour infusion), as tolerated, should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixazomib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ixazomib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: RifAMPin may increase the metabolism of LamoTRIgine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lapatinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lapatinib.  Management: If therapy overlap cannot be avoided, consider titrating lapatinib gradually from 1,250 mg/day up to 4,500 mg/day (HER2 positive metastatic breast cancer) or 1,500 mg/day up to 5,500 mg/day (hormone receptor/HER2 positive breast cancer) as tolerated.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ledipasvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Ledipasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: RifAMPin may increase serum concentrations of the active metabolite(s) of Leflunomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lesinurad: CYP2C9 Inducers (Moderate) may decrease the serum concentration of Lesinurad. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Letermovir: RifAMPin may decrease the serum concentration of Letermovir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong CYP3A4 inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lopinavir: RifAMPin may enhance the adverse/toxic effect of Lopinavir. Specifically, the risk of hepatocellular toxicity may be increased. RifAMPin may decrease the serum concentration of Lopinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lornoxicam: CYP2C9 Inducers (Moderate) may decrease the serum concentration of Lornoxicam. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Losartan: RifAMPin may decrease the serum concentration of Losartan. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumefantrine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lumefantrine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lurasidone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Lurasidone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macitentan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Macitentan. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macrolide Antibiotics: May decrease the metabolism of Rifamycin Derivatives.<b> Exceptions: </b>Azithromycin (Systemic); Fidaxomicin; Roxithromycin; Spiramycin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Manidipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Manidipine.  Management: Consider avoiding concomitant use of manidipine and strong CYP3A4 inducers. If combined, monitor closely for decreased manidipine effects and loss of efficacy. Increased manidipine doses may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maraviroc: CYP3A4 Inducers (Strong) may decrease the serum concentration of Maraviroc.  Management: Increase maraviroc adult dose to 600 mg twice daily when used with strong CYP3A4 inducers. This does not apply to patients also receiving strong CYP3A4 inhibitors. Do not use maraviroc with strong CYP3A4 inducers in patients with CrCl less than 30 mL/min.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methadone: Rifamycin Derivatives may decrease the serum concentration of Methadone.  Management: Seek alternatives when possible.  If used concomitantly, monitor closely for symptoms of methadone withdrawal upon rifamycin derivative initiation, and for excess sedation upon rifamycin derivative discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MethylPREDNISolone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose increases in patients receiving strong CYP3A4 inducers and monitor closely for reduced steroid efficacy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Midostaurin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Midostaurin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: CYP3A4 Inducers (Strong) may decrease the serum concentration of MiFEPRIStone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: RifAMPin may decrease the serum concentration of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirodenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Mirodenafil.  Management: Consider avoiding the concomitant use of mirodenafil and strong CYP3A4 inducers. If combined, monitor for decreased mirodenafil effects. Mirodenafil dose increases may be required to achieve desired effects.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Morphine (Systemic): RifAMPin may decrease the serum concentration of Morphine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mycophenolate: Rifamycin Derivatives may decrease the serum concentration of Mycophenolate. Specifically, rifamycin derivatives may decrease the concentration of the active metabolite mycophenolic acid. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naldemedine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naldemedine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nalmefene: RifAMPin may decrease the serum concentration of Nalmefene. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naloxegol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Naloxegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelfinavir: RifAMPin may decrease the serum concentration of Nelfinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neratinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Neratinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Netupitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Netupitant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nevirapine: RifAMPin may decrease the serum concentration of Nevirapine.  Management: Avoid whenever possible. When this combination is necessary, use immediate-release nevirapine (avoid extended-release nevirapine) at a dose of 200 mg twice daily with no lead-in (per adult/adolescent HIV guidelines).  Monitor nevirapine response closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NIFEdipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NIFEdipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nilotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nilotinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">NiMODipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of NiMODipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nintedanib: Combined Inducers of CYP3A4 and P-glycoprotein may decrease the serum concentration of Nintedanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nisoldipine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Nisoldipine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitrazepam: RifAMPin may decrease the serum concentration of Nitrazepam.  Management: Monitor closely for reduced effects of nitrazepam.  When possible, consider alternatives to one of these drugs, or increases in initial nitrazepam doses.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Olaparib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Olaparib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Omeprazole: RifAMPin may decrease the serum concentration of Omeprazole. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Osimertinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Osimertinib. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OXcarbazepine: RifAMPin may decrease serum concentrations of the active metabolite(s) of OXcarbazepine. Specifically, concentrations of the major active 10-monohydroxy metabolite may be reduced. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OxyCODONE: RifAMPin may decrease the serum concentration of OxyCODONE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palbociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Palbociclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Paliperidone: Inducers of CYP3A4 (Strong) and P-glycoprotein may decrease the serum concentration of Paliperidone.  Management: Avoid using the 3-month extended-release injectable suspension (Invega Trinza) with inducers of both CYP3A4 and P-glycoprotein during the 3-month dosing interval if possible. If combination is necessary, consider using extended-release tablets.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: CYP3A4 Inducers (Strong) may decrease the serum concentration of Panobinostat. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PAZOPanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Perampanel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Perampanel.  Management: Increase the perampanel starting dose to 4 mg/day when perampanel is used concurrently with moderate and strong CYP3A4 inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: RifAMPin may decrease the serum concentration of Phenytoin.  Management: Seek alternatives when possible. If used together, monitor closely for decreased serum phenytoin concentrations following rifampin initiation/dose increase, or increased concentrations and toxic effects following rifampin discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimavanserin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pimavanserin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Piperaquine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Piperaquine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitavastatin: Rifamycin Derivatives may increase the serum concentration of Pitavastatin.  Management: Limit pitavastatin dose to a maximum of 2 mg/day with concurrent rifampin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Pitolisant. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PONATinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of PONATinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prasugrel: RifAMPin may diminish the antiplatelet effect of Prasugrel. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Praziquantel: CYP3A4 Inducers (Strong) may decrease the serum concentration of Praziquantel.  Management: Avoid concomitant use of praziquantel with strong CYP3A4 inducers. Discontinue rifampin 4 weeks prior to initiation of praziquantel therapy. Rifampin may be resumed the day following praziquantel completion.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PrednisoLONE (Systemic): CYP3A4 Inducers (Strong) may decrease the serum concentration of PrednisoLONE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PredniSONE: CYP3A4 Inducers (Strong) may decrease the serum concentration of PredniSONE. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Rifamycin Derivatives may decrease the serum concentration of Progestins (Contraceptive). Contraceptive failure is possible.  Management: Contraceptive failure is possible.  Use of an alternative, nonhormonal contraceptive is recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propacetamol: RifAMPin may increase the metabolism of Propacetamol. . This may 1) diminish the desired effects of propacetamol; and 2) increase the risk of liver damage. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propafenone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Propofol: RifAMPin may enhance the hypotensive effect of Propofol.  Management: Note that use of propofol in a patient who has been taking rifampin may result in clinically significant hypotension.  If possible, avoid use of this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prothionamide: RifAMPin may enhance the hepatotoxic effect of Prothionamide.  Management: Avoid concomitant use of prothionamide and rifampin if possible. If combined use is considered necessary, monitor patients closely for signs and symptoms of hepatotoxicity (eg, jaundice, elevations in liver function tests).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pyrazinamide: May enhance the hepatotoxic effect of RifAMPin. Severe (even fatal) liver injury has been reported in patients receiving these 2 drugs as a 2-month treatment regimen for latent TB infection.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QUEtiapine: CYP3A4 Inducers (Strong) may decrease the serum concentration of QUEtiapine.  Management: An increase in quetiapine dose (as much as 5 times the regular dose) may be required to maintain therapeutic benefit. Reduce the quetiapine dose back to the previous/regular dose within 7-14 days of discontinuing the inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNIDine: Rifamycin Derivatives may decrease the serum concentration of QuiNIDine.  Management: Consider alternatives to combination treatment with quinidine and rifampin due to large potential decreases in quinidine concentrations. Monitor for decreased quinidine concentrations/effects with initiation/dose increase of any rifamycin derivative.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: RifAMPin may decrease the serum concentration of QuiNINE. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Radotinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Radotinib.  Management: Consider alternatives to this combination when possible as the risk of radotinib treatment failure may be increased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Raltegravir: RifAMPin may decrease the serum concentration of Raltegravir.  Management: Increase raltegravir dose to 800 mg twice daily (adult dose) when used concomitantly with rifampin. Concurrent use of rifampin with once-daily raltegravir (Isentress HD) is not recommended.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ramelteon. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: RifAMPin may decrease the serum concentration of Ranolazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reboxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Reboxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Regorafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Regorafenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Repaglinide: RifAMPin may decrease the serum concentration of Repaglinide.  Management: Consider alternatives to this combination. Dose timing may substantially affect this interaction; in clinical studies, the lowest magnitude of interaction was seen when repaglinide was given 1 h after rifampin (compared to 0, 12, or 24 h).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ribociclib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ribociclib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rilpivirine: Rifamycin Derivatives may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritonavir: RifAMPin may decrease the serum concentration of Ritonavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rivaroxaban: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rivaroxaban. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: RifAMPin may decrease the serum concentration of Roflumilast.  Management: Roflumilast U.S. prescribing information recommends against combining rifampin with roflumilast.  The Canadian product monograph makes no such recommendation but notes that rifampin may reduce roflumilast therapeutic effects.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rolapitant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Rolapitant.  Management: Avoid rolapitant use in patients requiring chronic administration of strong CYP3A4 inducers.  Monitor for reduced rolapitant response and the need for alternative or additional antiemetic therapy even with shorter-term use of such inducers.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RomiDEPsin: RifAMPin may increase the serum concentration of RomiDEPsin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ruxolitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ruxolitinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saquinavir: RifAMPin may enhance the adverse/toxic effect of Saquinavir. Specifically, the risk of hepatocellular toxicity may be increased. RifAMPin may decrease the serum concentration of Saquinavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SAXagliptin: CYP3A4 Inducers (Strong) may decrease the serum concentration of SAXagliptin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selexipag: RifAMPin may decrease serum concentrations of the active metabolite(s) of Selexipag. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sertraline: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Simeprevir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Simeprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sirolimus.  Management: Avoid concomitant use of strong CYP3A4 inducers and sirolimus if possible. If combined, monitor for reduced serum sirolimus concentrations. Sirolimus dose increases will likely be necessary to prevent subtherapeutic sirolimus levels.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sofosbuvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Sofosbuvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sonidegib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Sonidegib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SORAfenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SORAfenib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUFentanil: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUFentanil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: RifAMPin may decrease the serum concentration of Sulfonylureas.  Management: Seek alternatives to these combinations when possible.  Monitor closely for diminished therapeutic effects of sulfonylureas if rifampin is initiated/dose increased, or enhanced effects if rifampin is discontinued/dose decreased.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SUNItinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of SUNItinib.  Management: Avoid when possible. If such a combination cannot be avoided, consider increasing sunitinib dose and monitor clinical response and toxicity closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suvorexant: CYP3A4 Inducers (Strong) may decrease the serum concentration of Suvorexant. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Rifamycin Derivatives may decrease the serum concentration of Tacrolimus (Systemic).  Management: Consider alternatives when possible.  If these combination are used, monitor for reduced tacrolimus concentrations/effects following rifamycin initiation/dose increase, or increased concentrations/effects following rifamycin discontinuation/dose decrease.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tadalafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tadalafil.  Management: Erectile dysfunction: monitor for decreased effectiveness - no standard dose adjustments recommended.  Avoid use of tadalafil for pulmonary arterial hypertension in patients receiving a strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: Rifamycin Derivatives may increase the metabolism of Tamoxifen. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tamoxifen: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. CYP3A4 Inducers (Strong) may decrease the serum concentration of Tamoxifen.  Management: Consider alternatives to concomitant use of strong CYP3A4 inducers and tamoxifen. If the combination cannot be avoided, monitor for reduced therapeutic effects of tamoxifen.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tasimelteon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tasimelteon. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Telaprevir: RifAMPin may decrease the serum concentration of Telaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: Rifamycin Derivatives may decrease the serum concentration of Temsirolimus. Rifamycins will likely cause an even greater decrease in the concentration of the active metabolite sirolimus.  Management: Temsirolimus prescribing information recommends against coadministration with strong CYP3A4 inducers such as rifampin; however, if concurrent therapy is necessary, an increase in temsirolimus adult dose to 50 mg/week should be considered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Temsirolimus: CYP3A4 Inducers (Strong) may decrease the serum concentration of Temsirolimus.  Management: Consider increasing the dose of temsirolimus to 50 mg IV/week (from 25 mg IV/week) if a concomitant CYP3A4 strong inducer is necessary.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tenofovir Alafenamide: RifAMPin may decrease the serum concentration of Tenofovir Alafenamide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Terbinafine (Systemic): RifAMPin may decrease the serum concentration of Terbinafine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Teriflunomide: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetrahydrocannabinol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tetrahydrocannabinol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazolidinediones: RifAMPin may increase the metabolism of Thiazolidinediones.  Management: Consider alternatives to the concomitant use of rifampin with thiazolidinedione antidiabetic agents.  Monitor patients receiving these combinations for decreased effects of the thiazolidinedione derivative.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thyroid Products: RifAMPin may decrease the serum concentration of Thyroid Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TiaGABine: CYP3A4 Inducers (Strong) may decrease the serum concentration of TiaGABine.  Management: Approximately 2-fold higher tiagabine doses and a more rapid dose titration will likely be required in patients concomitantly taking a strong CYP3A4 inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ticagrelor: CYP3A4 Inducers (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inducers (Strong) may decrease the serum concentration of Ticagrelor. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tipranavir: RifAMPin may decrease the serum concentration of Tipranavir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tolvaptan.  Management: If concurrent use is necessary, increased doses of tolvaptan (with close monitoring for toxicity and clinical response) may be needed.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Toremifene: CYP3A4 Inducers (Strong) may decrease the serum concentration of Toremifene. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trabectedin: CYP3A4 Inducers (Strong) may decrease the serum concentration of Trabectedin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tropisetron: CYP3A4 Inducers (Strong) may decrease the serum concentration of Tropisetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Udenafil: CYP3A4 Inducers (Strong) may decrease the serum concentration of Udenafil. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ulipristal: CYP3A4 Inducers (Strong) may decrease the serum concentration of Ulipristal. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valbenazine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Valbenazine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: RifAMPin may decrease the serum concentration of Valproate Products. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vandetanib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vandetanib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: CYP2B6 Inducers (Moderate) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: CYP3A4 Inducers (Strong) may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Velpatasvir: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Velpatasvir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vemurafenib: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vemurafenib.  Management: Avoid concurrent use of vemurafenib with a strong CYP3A4 inducer and replace with another agent when possible. If a strong CYP3A4 inducer is indicated and unavoidable, the dose of vemurafenib may be increased by 240 mg (1 tablet) as tolerated.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: CYP3A4 Inducers (Strong) may decrease the serum concentration of Venetoclax. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vilazodone: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vilazodone.  Management: Consider increasing vilazodone dose by as much as 2-fold (do not exceed 80 mg/day), based on response, in patients receiving strong CYP3A4 inducers for &gt; 14 days.  Reduce to the original vilazodone dose over 1-2 weeks after inducer discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): CYP3A4 Inducers (Strong) may decrease the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vinflunine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Rifamycin Derivatives may increase the metabolism of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vorapaxar: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vorapaxar. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: May increase the serum concentration of Rifamycin Derivatives. Rifamycin Derivatives may decrease the serum concentration of Voriconazole.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vortioxetine: CYP3A4 Inducers (Strong) may decrease the serum concentration of Vortioxetine.  Management: Consider increasing the vortioxetine dose to no more than 3 times the original dose when used with a strong drug metabolism inducer for more than 14 days. The vortioxetine dose should be returned to normal within 14 days of stopping the strong inducer.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voxilaprevir: RifAMPin may increase the serum concentration of Voxilaprevir. Specifically, a single dose of rifampin may increase voxilaprevir concentrations, while chronic daily use of rifampin may decrease voxilaprevir concentrations. RifAMPin may decrease the serum concentration of Voxilaprevir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zaleplon: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zaleplon.  Management: Consider the use of an alternative hypnotic that is not metabolized by CYP3A4 in patients receiving strong CYP3A4 inducers. If zalephon is combined with a strong CYP3A4 inducer, monitor for decreased effectiveness of zaleplon.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zidovudine: Rifamycin Derivatives may decrease the serum concentration of Zidovudine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zolpidem: RifAMPin may decrease the serum concentration of Zolpidem. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Zuclopenthixol: CYP3A4 Inducers (Strong) may decrease the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218183\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Food decreases the extent of absorption; rifampin concentrations may be decreased if taken with food. Management: Administer on an empty stomach with a glass of water (ie, 1 hour prior to, or 2 hours after meals or antacids). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218154\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218169\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. Rifampin crosses the human placenta. Postnatal hemorrhages have been reported in the infant and mother with administration during the last few weeks of pregnancy.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Maternal treatment of tuberculosis is recommended when the probability of maternal disease is moderate to high due to the risk of infection to the fetus (ATC/CDC 2003). Rifampin may be considered for use as an alternative agent in pregnant women for the treatment of mild illness due to human anaplasmosis (also known as human granulocytic anaplasmosis [HGA]); case reports have shown favorable maternal and pregnancy outcomes in small numbers of rifampin-treated pregnant women (CDC [Biggs 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10924208\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Rifampin is present in breast milk (Vorherr 1974). Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. In the treatment of drug-susceptible tuberculosis, use of rifampin is not a contraindication to breastfeeding in women deemed non-infectious who are treated with first-line agents (ie, rifampin). The amount of drug in breast milk is considered insufficient for the treatment of tuberculosis in breastfed infants (Nahid 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218156\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic (baseline and every 2 to 4 weeks during therapy) monitoring of liver function (AST, ALT, bilirubin), CBC, mental status, sputum culture, chest x-ray 2 to 3 months into treatment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50186919\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>TB treatment: Target peak: </b>&ge;8 mcg/mL at 2 and 6 hours post-dose (Alsultan 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218145\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits bacterial RNA synthesis by binding to the beta subunit of DNA-dependent RNA polymerase, blocking RNA transcription</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218165\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: &le;24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Well absorbed; food may delay or slightly reduce peak </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Highly lipophilic; crosses blood-brain barrier well </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Relative diffusion from blood into CSF: Adequate with or without inflammation (exceeds usual MICs) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF:blood level ratio: Inflamed meninges: 25% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 80% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; undergoes enterohepatic recirculation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 3-4 hours; prolonged with hepatic impairment; End-stage renal disease: 1.8-11 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: Oral: 2-4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (60% to 65%) and urine (~30%) as unchanged drug</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218168\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (Rifadin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $117.17</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsules</b> (RifAMPin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mg (30): $97.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mg (100): $207.04</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Rifadin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (1): $214.27</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (RifAMPin Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">600 mg (1): $135.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (RifAMPin+SyrSpend SF PH4 Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/mL (120 mL): $328.13</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218171\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Arficin (HR);</li>\n      <li>Bactromax (CO);</li>\n      <li>Benemicin (CZ, LV, RU, SK);</li>\n      <li>Corifam (ID);</li>\n      <li>Eremfat (CZ, DE);</li>\n      <li>Fuhe (CN);</li>\n      <li>Lyrimpin (VN);</li>\n      <li>Macox (LK);</li>\n      <li>Maficin (PH);</li>\n      <li>Makoks (UA);</li>\n      <li>Manorifcin (TH);</li>\n      <li>Mycin (BD);</li>\n      <li>Myconil (BD);</li>\n      <li>Oxitrin (PY);</li>\n      <li>Ramicin (ID);</li>\n      <li>Rifacilin (IN);</li>\n      <li>Rifacin (AE, PH, QA, SA);</li>\n      <li>Rifacure (ZW);</li>\n      <li>Rifadex (EC);</li>\n      <li>Rifadin (AE, AR, AU, BB, BF, BH, BJ, CI, CR, CY, DO, EG, ET, GB, GH, GM, GN, GR, GT, HK, HN, IE, IQ, IR, IT, JO, KE, KW, LB, LR, LY, MA, ML, MR, MT, MU, MW, MX, NE, NG, NI, NL, NZ, OM, PA, PK, PT, QA, SA, SC, SD, SE, SL, SN, SV, SY, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Rifadine (BE, FR, LU, VN);</li>\n      <li>Rifaldin (BR, CL, ES);</li>\n      <li>Rifamcin (TH);</li>\n      <li>Rifamed (HU);</li>\n      <li>Rifampicin (PL);</li>\n      <li>Rifampicin Labatec (CH);</li>\n      <li>Rifampin (KR);</li>\n      <li>Rifapin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);</li>\n      <li>Rifarad (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Rifaren (MT, SG, TR);</li>\n      <li>Rifarm (FI);</li>\n      <li>Rifasynt (CY, JO, MY);</li>\n      <li>Rifatan (BD);</li>\n      <li>Rifocina (PE);</li>\n      <li>Rifocina Spray (CO);</li>\n      <li>Rifodex (KR);</li>\n      <li>Rifoldin (AT);</li>\n      <li>Rifoldine (CH);</li>\n      <li>Rimactan (AT, BG, CH, DK, ES, FR, HR, IS, LU, MX, NL, NO, SE, SI, UY, VE, VN);</li>\n      <li>Rimactane (BD, BF, BH, BJ, BM, BS, BZ, CI, ET, GB, GH, GM, GN, GY, ID, IL, IN, JM, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, QA, SA, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Rimactan[inj.] (CH);</li>\n      <li>Rimafed (PH);</li>\n      <li>Rimapen (FI);</li>\n      <li>Rimecin (TH);</li>\n      <li>Rimpacin (AE, BF, BH, BJ, CI, CY, EG, ET, GH, GM, GN, IQ, IR, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, NE, NG, OM, QA, SA, SC, SD, SL, SN, SY, TN, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Rimpin (IN);</li>\n      <li>Rimycin (AU);</li>\n      <li>Ripin (TW);</li>\n      <li>Shu Lan Xin (CN);</li>\n      <li>TB Rif (ID);</li>\n      <li>Tubocin (HU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Acocella G, &ldquo;Clinical Pharmacokinetics of Rifampicin,&ldquo; <i>Clin Pharmacokinet</i>, 1978, 3(2):108-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/346286/pubmed\" target=\"_blank\" id=\"346286\">346286</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Advenier C, Gobert C, Houin G, et al, &ldquo;Pharmacokinetic Studies of Rifampicin in the Elderly,&rdquo; <i>Ther Drug Monit</i>, 1983, 5(1):61-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/6845400/pubmed\" target=\"_blank\" id=\"6845400\">6845400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds; <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Infectious Diseases, &ldquo;Chemotherapy for Tuberculosis in Infants and Children,&rdquo; <i>Pediatrics</i>, 1992, 89(1):161-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/1728006/pubmed\" target=\"_blank\" id=\"1728006\">1728006</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Thoracic Society (ATC); CDC; Infectious Diseases Society of America (IDSA). Treatment of Tuberculosis [published correction appears in <i>MMWR Recomm Rep</i>. 2005;53(51):1203]. <i>MMWR Recomm Rep</i>. 2003;52(RR-11):1-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/12836625/pubmed\" target=\"_blank\" id=\"12836625\">12836625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alsultan A, Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis: An update. <i>Drugs</i>. 2014; 74:839.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/24846578/pubmed\" target=\"_blank\" id=\"24846578\">24846578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ASHP. Standardize 4 Safety Initiative Compounded Oral Liquid Version 1.01. July 2017. https://www.ashp.org/-/media/assets/pharmacy-practice/s4s/docs/s4s-ashp-oral-compound-liquids.ashx?la=en&amp;hash=4C2E4F370B665C028981B61F6210335AD5D0D1D6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Askgaard DS, Wilcke T, and Dossing M, &ldquo;Hepatotoxicity Caused by the Combined Action of Isoniazid and Rifampin,&rdquo; <i>Thorax</i>, 1995, 50(2):213-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/7701468/pubmed\" target=\"_blank\" id=\"7701468\">7701468</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baddour LM, Wilson WR, Bayer AS, et al; American Heart Association Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Stroke Council. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association [published correction appears in <i>Circulation</i>. 2015;132(17):e215]. <i>Circulation</i>. 2015;132(15):1435-1486. doi: 10.1161/CIR.0000000000000296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/26373316/pubmed\" target=\"_blank\" id=\"26373316\">26373316</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al; American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee of the Council on Cardiovascular Disease in the Young and the Council on Cardiovascular and Stroke Nursing. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association. <i>Circulation.</i> 2015;132(15):1487-1515. doi: 10.1161/CIR.0000000000000298.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bass JB Jr, Farer LS, Hopewell PC, et al, &ldquo;Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children,&rdquo; <i>Am J Respir Crit Care Med</i>, 1994, 149(5):1359-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/8173779/pubmed\" target=\"_blank\" id=\"8173779\">8173779</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/27172113/pubmed\" target=\"_blank\" id=\"27172113\">27172113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Borcherding SM, Baciewicz AM, and Self TH, &ldquo;Update on Rifampin Drug Interactions. II,&rdquo; <i>Arch Intern Med</i>, 1992, 152(4):711-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/1558427/pubmed\" target=\"_blank\" id=\"1558427\">1558427</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Briere EC, Rubin L, Moro PL, et al. Prevention and control of haemophilus influenzae type b disease: recommendations of the advisory committee on immunization practices (ACIP). <i>MMWR Recomm Rep</i>. 2014;63(RR-01):1-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/24572654/pubmed\" target=\"_blank\" id=\"24572654\">24572654</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control, &ldquo;Update: Adverse Event Data and Revised American Thoracic Society/CDC Recommendations Against the Use of Rifampin and Pyrazinamide for Treatment of Latent Tuberculosis Infection - United States, 2003,&rdquo; <i>MMWR</i>, 52(31);735-9. Available at <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5231a4.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daher R, Haidar JH, and Al-Amin H, &ldquo;Rifampin Interference With Opiate Immunoassays,&rdquo; <i>Clin Chem</i>, 2002, 48(1):203-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/11751562/pubmed\" target=\"_blank\" id=\"11751562\">11751562</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davidson PT and Le HQ, &ldquo;Drug Treatment of Tuberculosis - 1992,&rdquo; <i>Drugs</i>, 1992, 43(5):651-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/1379145/pubmed\" target=\"_blank\" id=\"1379145\">1379145</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    De Vriese AS, Robbrecht DL, Vanholder RC, et al, &ldquo;Rifampicin-Associated Acute Renal Failure: Pathophysiologic, Immunologic, and Clinical Features,&rdquo; <i>Am J Kidney Dis</i>, 1998, 31(1):108-15.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/9428460/pubmed\" target=\"_blank\" id=\"9428460\">9428460</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children. Department of Health and Human Services. November 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf</a>.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. October 2014. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed November 12, 2014</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Drugs for Tuberculosis,&rdquo; <i>Med Lett Drugs Ther</i>, 1993, 35(908):99-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/8412982/pubmed\" target=\"_blank\" id=\"8412982\">8412982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. <i>Thorax</i>. 2016;71 Suppl 1:i1-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/26666259/pubmed\" target=\"_blank\" id=\"26666259\">26666259</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Furlan V, Perello L, Jacquemin E, et al, &ldquo;Interactions Between FK506 and Rifampicin or Erythromycin in Pediatric Liver Recipients,&rdquo; <i>Transplantation</i>, 1995, 59(8):1217-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/7537398/pubmed\" target=\"_blank\" id=\"7537398\">7537398</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gould FK, Denning DW, Elliott TS, et al, &ldquo;Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy,&rdquo; <i>J Antimicrob Chemother</i>, 2012, 67(2):269-89.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/22086858/pubmed\" target=\"_blank\" id=\"22086858\">22086858</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griffith DE, Aksamit T, Brown-Elliott BA, et al, &ldquo;An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases,&rdquo; <i>Am J Respir Crit Care Med</i>, 2007, 175(4):367-416.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/17277290/pubmed\" target=\"_blank\" id=\"17277290\">17277290</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22296864\"></a>Hashemi SH, Gachkar L, Keramat F, et al. Comparison of doxycycline-streptomycin, doxycycline-rifampin, and ofloxacin-rifampin in the treatment of brucellosis: a randomized clinical trial. <i>Int J Infect Dis</i>. 2012;16(4):e247-251.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/22296864/pubmed\" target=\"_blank\" id=\"22296864\">22296864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Havlir DV and Barnes PF, &ldquo;Tuberculosis in Patients With Human Immunodeficiency Virus Infection,&rdquo; <i>N Engl J Med</i>, 1999, 340(5):367-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/9929528/pubmed\" target=\"_blank\" id=\"9929528\">9929528</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Health Resources and Services Administration (HRSA). National Hansen's Disease (Leprosy) Program: Recommended Treatment Regimens. http://www.hansensdisease/diagnosis/recommendedtreatment.html. Accessed on March 31, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herrera Trevilla P, Ortiz Jimenez E, Tena T, et al, &ldquo;Presence of Rifampicin in Urine Causes Cross-Reactivity With Opiates Using the KIMS Method,&rdquo; <i>J Anal Toxicol</i>, 1995, 19(3):200.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/7564301/pubmed\" target=\"_blank\" id=\"7564301\">7564301</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holdiness MR, &ldquo;A Review of the Redman Syndrome and Rifampicin Overdose,&rdquo; <i>Med Toxicol Adverse Drug Exp</i>, 1989, 4(6):444-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/2689837/pubmed\" target=\"_blank\" id=\"2689837\">2689837</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iseman MD, &ldquo;Treatment of Multidrug-Resistant Tuberculosis,&rdquo; <i>N Engl J Med</i>, 1993, 329(11):784-91.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/8350889/pubmed\" target=\"_blank\" id=\"8350889\">8350889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kindelan JM, Serrano I, Jurado R, et al, &ldquo;Rifampin-Induced Severe Thrombocytopenia in a Patient With Pulmonary Tuberculosis,&rdquo; <i>Ann Pharmacother</i>, 1994, 28(11):1304-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/7849351/pubmed\" target=\"_blank\" id=\"7849351\">7849351</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Liu C, Bayer A, Cosgrove SE, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children: Executive Summary. <i>Clin Infect Dis</i>, 2011; 52(3):285-292.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/21217178/pubmed\" target=\"_blank\" id=\"21217178\">21217178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lundstrom TS and Sobel JD, &ldquo;Vancomycin, Trimethoprim-Sulfamethoxazole, and Rifampin,&rdquo; <i>Infect Dis Clin North Am</i>, 1995, 9(3):747-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/7490442/pubmed\" target=\"_blank\" id=\"7490442\">7490442</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahata MC, Morosco RS, and Hipple TF, &ldquo;Effect of Preparation Method and Storage on Rifampin Concentration in Suspensions,&rdquo; <i>Ann Pharmacother</i>, 1994, 28(2):182-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/8173129/pubmed\" target=\"_blank\" id=\"8173129\">8173129</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. <i>Clin Infect Dis</i>. 2016;63(7):e147-e195. doi: 10.1093/cid/ciw376.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/27516382/pubmed\" target=\"_blank\" id=\"27516382\">27516382</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Noble A, &ldquo;Antituberculous Therapy and Acute Liver Failure,&rdquo; <i>Lancet</i>, 1995, 345(8953):867.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Orisakwe OE, Dioka CE, Orish CN, et al, &ldquo;Charcoal and Rifampicin Pharmacokinetics,&rdquo; <i>Am J Therapeut</i>, 1995, 68-70.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Osmon DR, Berbari EF, Berendt AR, et al, &ldquo;Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2013, 56(1):e1-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/23223583/pubmed\" target=\"_blank\" id=\"23223583\">23223583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plomp TA, Battista HJ, Unterdorfer H, et al, &ldquo;A Case of Fatal Poisoning by Rifampicin,&rdquo; <i>Arch Toxicol</i>, 1981, 48(4):245-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/7316759/pubmed\" target=\"_blank\" id=\"7316759\">7316759</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Prevention and Treatment of Tuberculosis Among Patients Infected With Human Immunodeficiency Virus: Principles of Therapy and Revised Recommendations. Centers for Disease Control and Prevention,&rdquo; <i>MMWR Recomm Rep</i>, 1998, 47(RR-20):1-58.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rajagopalan S, Yoshikawa TT. Tuberculosis in long-term-care facilities. <i>Infect Control Hosp Epidemiol</i>. 2000;21(9):611-615.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/11001270/pubmed\" target=\"_blank\" id=\"11001270\">11001270</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rifadin (rifampin) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis US LLC; January 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rifadin (rifampin) [product monograph]. Laval, Quebec, Canada: Sanofi-Aventis Canada Inc; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shulman ST, Bisno AL, Clegg HW, et al, &ldquo;Clinical Practice Guideline for the Diagnosis and Management of Group A Streptococcal Pharyngitis: 2012 Update by the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2012, 55(10):e86-102.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/22965026/pubmed\" target=\"_blank\" id=\"22965026\">22965026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"8540716\"></a>Solera J, Rodr&iacute;guez-Zapata M, Geijo P, et al. Doxycycline-rifampin versus doxycycline-streptomycin in treatment of human brucellosis due to Brucella melitensis. The GECMEI Group. Grupo de Estudio de Castilla-la Mancha de Enfermedades Infecciosas. <i>Antimicrob Agents Chemother</i>. 1995;39(9):2061-2067.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/8540716/pubmed\" target=\"_blank\" id=\"8540716\">8540716</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR, &ldquo;Modern Approach to the Diagnosis and Treatment of Tuberculosis in Children,&rdquo; <i>Pediatr Clin North Am</i>, 1988, 35(3):441-64.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Starke JR, &ldquo;Multidrug Therapy for Tuberculosis in Children,&rdquo; <i>Pediatr Infect Dis J</i>, 1990, 9(11):785-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/2124671/pubmed\" target=\"_blank\" id=\"2124671\">2124671</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thrupp L, Bradley S, Smith P, et al. Tuberculosis prevention and control in long-term-care facilities for older adults. <i>Infect Control Hosp Epidemiol</i>. 2004;25(12):1097-1108.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/15636299/pubmed\" target=\"_blank\" id=\"15636299\">15636299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Treatment of Latent Tuberculosis Infection (LTBI), Last Updated: April 8, 2004.&rdquo; Available at <a href=\"http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm\" target=\"_blank\">http://www.cdc.gov/nchstp/tb/pubs/tbfactsheets/250110.htm</a>. Last accessed February 16, 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Hartman BJ, Kaplan SL, et al, &ldquo;Practice Guidelines for the Management of Bacterial Meningitis,&rdquo; <i>Clin Infect Dis</i>, 2004, 39(9):1267-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/15494903/pubmed\" target=\"_blank\" id=\"15494903\">15494903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Van Scoy RE and Wilkowske CJ, &ldquo;Antituberculosis Agents,&rdquo; <i>Mayo Clin Proc</i>, 1992, 67(2):179-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/1347579/pubmed\" target=\"_blank\" id=\"1347579\">1347579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vesely JJ, Pien FD, and Pien BC, &ldquo;Rifampin, a Useful Drug for Nonmycobacterial Infections,&rdquo; <i>Pharmacotherapy</i>, 1998, 18(2):345-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/9545154/pubmed\" target=\"_blank\" id=\"9545154\">9545154</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vorherr H. Drug excretion in breast milk. <i>Postgrad Med</i>. 1974;56(4):97-104.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/4606454 /pubmed\" target=\"_blank\" id=\"4606454 \">4606454 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walker-Renard P, &ldquo;Pruritus Associated With Intravenous Rifampin,&rdquo; <i>Ann Pharmacother</i>, 1995, 29(3):267-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/7606073/pubmed\" target=\"_blank\" id=\"7606073\">7606073</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wong P, Bottoroff MB, Heritage RW, et al, &ldquo;Acute Rifampin Overdose: A Pharmacokinetic Study and Review of the Literature,&rdquo; <i>J Pediatr</i>, 1984, 104(5):781-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/6371210/pubmed\" target=\"_blank\" id=\"6371210\">6371210</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization, Brucellosis in humans and animals, 2006. Available at http://www.who.int/csr/resources/publications/Brucellosis.pdf.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization. WHO Expert Committee on Leprosy. <i>World Health Organ Tech Rep Ser</i>. 2012;(968):1-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/22970604/pubmed\" target=\"_blank\" id=\"22970604\">22970604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2006;43(9):1089-1134.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/17029130/pubmed\" target=\"_blank\" id=\"17029130\">17029130</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshikawa TT, &ldquo;Tuberculosis in Aging Adults,&rdquo; <i>J Am Geriatr Soc</i>, 1992, 40(2):178-87.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rifampin-rifampicin-drug-information/abstract-text/1740604/pubmed\" target=\"_blank\" id=\"1740604\">1740604</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9864 Version 229.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F218187\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F218188\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F218238\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F218192\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F218215\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F218193\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F218194\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F218195\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F218158\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F218142\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50027244\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F218162\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F218161\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25715118\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F218247\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F218149\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F218166\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F218146\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F218233\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F218151\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F218183\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F218154\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F218169\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10924208\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F218156\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F50186919\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F218145\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F218165\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F218168\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F218171\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9864|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rifampin-rifampicin-patient-drug-information\" class=\"drug drug_patient\">Rifampin (rifampicin): Patient drug information</a></li><li><a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">Rifampin (rifampicin): Pediatric drug information</a></li></ul></div></div>","javascript":null}